Impact of the various combinations of first-line and injectable drug resistance on negative treatment outcomes among patients with multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB)
| Groups | Treatment success | Adverse treatment outcome | Total | Unadjusted OR (95% CI) | Adjusted OR# (95% CI) |
| MDR-TB | |||||
| Susceptible to all first-line¶ | 4 (57.1) | 3 (42.9) | 7 | 1 | 1 |
| Resistant to one first-line+ | 35 (83.3) | 7 (16.7) | 42 | 0.27 (0.04–1.46) | 0.2 (0.03–1.29) |
| Resistant to two first-line+ | 123 (65.8) | 64 (34.2) | 187 | 0.69 (0.15–3.19) | 1.63 (0.13–21.31) |
| Resistant to one second-line + any fluoroquinolone | 22 (45.8) | 26 (54.2) | 48 | 2.6 (1.38–4.88) | 2.9 (1.51–5.63) |
| Susceptible to all second-line | 64 (82.1) | 14 (17.9) | 78 | 1 | 1 |
| Resistant to one second-line | 53 (74.7) | 18 (25.3) | 71 | 1.55 (0.71–3.41) | 1.31 (0.52–3.29) |
| Resistant to two or all second-line | 13 (72.2) | 5 (27.8) | 18 | 1.76 (0.54–5.74) | 1.85 (0.54–6.39) |
| XDR-TB | |||||
| Resistant to none or one first-line+ | 2 (66.7) | 1 (33.3) | 3 | 1 | 1 |
| Resistant to two first-line+ | 20 (44.4) | 25 (55.6) | 45 | 1.25 (0.07–21.26) | 1.17 (0.04–23.19) |
| Resistant to none or one second-line | 14 (53.8) | 12 (46.2) | 26 | 1 | 1 |
| Resistant to two second-line | 6 (42.9) | 8 (57.1) | 14 | 1.44 (0.39–5.39) | 0.95 (0.22–4.07) |
| Resistant to all second-line | 3 (37.5) | 5 (62.5) | 8 | 1.81 (0.35–9.24) | 0.94 (0.14–6.26) |
Data are presented as n (%), unless otherwise stated. #: adjusted for the main confounding variables, such as sex, age, HIV status, etc. ¶: except isoniazid and rifampicin; +: beyond rifampicin and isoniazid.